Background: CAR T-cells have shown impressive clinical responses in patients with hematologic malignancies, but barriers exist to broader patient access, these include personalized manufacturing, toxicity, and preconditioning chemotherapy. The current methods used to generate a CAR-T cell dose ex vivo are complex and hinder widespread application. Lipid nanoparticle technology has demonstrated the ability to deliver mRNA payloads to cells. A therapeutic platform based on that technology could provide an off-the-sh…

<div>Abstract<p>Myeloid-derived suppressor cells (MDSC) include immature monocytic (M-MDSC) and granulocytic (PMN-MDSC) cells that share the ability to suppress adaptive immunity and to hinder the effectiveness of anticancer treatments. Of note, in response to IFNγ, M-MDSCs release the tumor-promoting and immunosuppressive molecule nitric oxide (NO), whereas macrophages largely express antitumor properties. Investigating these opposing activities, we found that tumor-derived prostaglandin E2 (PGE2) ind…

<p>Stat1 peaks detected in p50-/- PEC stimulated with IFNγ for 2 hours as compared to WT PEC</p>

<p>selective gene expression alterations in p50-/- M-MDSC stimulated with IFNγ for 4 hours as compared to WT M-MDSC</p>

<p>Association of each induced gene to the nearest STAT1 peak according to the distance between the TSS (Transcription Start Site) of each gene and the summit of STAT1 induced peaks.</p>